Novartis Financial Results – Q2 2026
Novartis announces the company’s financial results for the second quarter and first half of 2026.
Novartis breaks ground on new RLT manufacturing site in Denton, Texas
Novartis' first Texas-based manufacturing facility expands US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Latest News
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
